ADRIAENS-LOUIS
ActiveSummary
ADRIAENS-LOUIS has been active since 2000 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €113,301 and a net result of €21,913. Equity has been stable since 2018 (±0.5% per year). Its solvency ranks better than 41% of 12,757 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 17-07-2000 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730and 4 others
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment unit
- 2.094.032.931 7020 Mons, since 09-10-2000
- Financial year end
- 31 December
- Peppol
- Reachable since 20-11-2020
Board and ownership
- PBX MANAGEMENTManaging director · permanent representative BERTIAUX Xavier
- LES PHARMACIES BENIT-DEHAUT-RIONDirector · permanent representative RION jean
- PHARMACIE DE MESSINES100%· score 532025 annual accounts of PHARMACIE DE MESSINES
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Gross margin
- €243,725
- ▲ 113%
- Turnover
- ≈ €1.1m
- estimated
- Profit
- €21,913
- Equity
- €113,301
- ▼ 1.8%
- Total assets
- €402,839
- ▼ 45.0%
- Employees on 31-12-2025
- 3
- 2025 accounts filed 21 days after the deadline
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskFounded in 2000Size: total assets €402,839Liquidity: current ratio 1.36, cash €81,663Show the evidence
Checked score
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 44% of them on solvency, 34% on liquidity, 48% on profitability and 35% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 12 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Recent changes
- · Gazette deed Resignations: SERVAIS Claire (director) and BOSSER Thierry (director)Appointment: PBX MANAGEMENT (managing director) · Permanent representative: BERTIAUX Xavier
- · Gazette deed Resignations: SERVAIS Claire (director) and BOSSER Thierry (director)Appointments: LES PHARMACIES BENIT-DEHAUT-RION (director) and PBX MANAGEMENT (director) · Permanent representatives: RION jean and BERTIAUX Xavier
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as ADRIAENS-LOUIS: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €388,000 and €490,000, founded between 1997 and 2004.
| Company | Total assets | Gross margin |
|---|---|---|
| ADRIAENS-LOUIS Mons | €402,839 | €243,725 |
| Apotheek G. Dezillie Duffel | €402,574 | €227,580 |
| Apotheek Hulsbosch Kristien Hamont-Achel | €419,337 | €223,244 |
| APOTHEEK DRIE FONTEINEN Tervuren | €387,846 | €236,609 |
| Pharmacie de Nassogne Nassogne | €445,155 | €237,892 |
| PHARMACIE MARCHAL Chièvres | €467,278 | €291,580 |
| PHARMACIE DE LA TOUR Anderlues | €490,336 | €229,372 |
Key facts about ADRIAENS-LOUIS
- What is the company number of ADRIAENS-LOUIS?
- The company number of ADRIAENS-LOUIS is 0472.411.279. The VAT number is the same number with BE in front: BE 0472.411.279.
- Where is ADRIAENS-LOUIS based?
- The registered office is at Grand-Rue 87, 7000 Mons.Company details
- What does ADRIAENS-LOUIS do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of ADRIAENS-LOUIS?
- The legal form of ADRIAENS-LOUIS is Public limited company (NV).
- When was ADRIAENS-LOUIS founded?
- ADRIAENS-LOUIS was founded on 17-07-2000.
- Is ADRIAENS-LOUIS still active?
- Yes, ADRIAENS-LOUIS is an active enterprise in the KBO register.
- How many employees does ADRIAENS-LOUIS have?
- ADRIAENS-LOUIS had an average of 2.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ADRIAENS-LOUIS fall under?
- In its 2025 annual accounts, ADRIAENS-LOUIS states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of ADRIAENS-LOUIS?
- The turnover in financial year 2025 is ≈ €1.1m. This figure is estimated from the gross margin of €243,725 and 51 comparable companies (NACE 477). It probably lies between €770,000 and €2.2m.
- Is ADRIAENS-LOUIS profitable?
- In financial year 2025, ADRIAENS-LOUIS made a profit of €21,913.
- Where can I find the annual accounts of ADRIAENS-LOUIS?
- ADRIAENS-LOUIS filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ADRIAENS-LOUIS due?
- ADRIAENS-LOUIS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.